Executive Management
Renay A. Ebelle, PhD, MBA
President & CEO
Dr. Ebelle is a seasoned industry leader with combined business and technical experience and over 20 years of experience in the pharmaceuticals, biologics and medical device industries.
Previously Dr. Ebelle was the Vice President at Renalex Group LLC, a key player in the life science industry providing regulatory, and market entry strategy, where he led global Regulatory and Clinical development projects. Prior to that, he was with Mela Sciences Inc. a leader in melanoma diagnostic, leading strategies for the regulatory, quality and clinical divisions which he help build. At Mela Sciences, his efforts led to the launch of the first-in-kind novel medical diagnostic device “MelaFind”, in the US and Europe. Prior to Mela, Dr. Ebelle worked at top fortune 500 companies including Johnson and Johnson, Watson Pharmaceuticals, and TyRx Pharma, where he held diverse senior management positions.
Dr. Ebelle graduated from the University of Ivory Coast with a Master of Sciences and a Doctorate in Biochemistry. He attended Columbia University where he received his PhD in cellular immunology. He holds a six sigma green belt for excellence from Lockheed Martin and an MBA from Rutgers University Business School with a focus on Pharmaceutical Management and finance. He is the author of several patents and co-authors of multiple scientific publications.
Previously Dr. Ebelle was the Vice President at Renalex Group LLC, a key player in the life science industry providing regulatory, and market entry strategy, where he led global Regulatory and Clinical development projects. Prior to that, he was with Mela Sciences Inc. a leader in melanoma diagnostic, leading strategies for the regulatory, quality and clinical divisions which he help build. At Mela Sciences, his efforts led to the launch of the first-in-kind novel medical diagnostic device “MelaFind”, in the US and Europe. Prior to Mela, Dr. Ebelle worked at top fortune 500 companies including Johnson and Johnson, Watson Pharmaceuticals, and TyRx Pharma, where he held diverse senior management positions.
Dr. Ebelle graduated from the University of Ivory Coast with a Master of Sciences and a Doctorate in Biochemistry. He attended Columbia University where he received his PhD in cellular immunology. He holds a six sigma green belt for excellence from Lockheed Martin and an MBA from Rutgers University Business School with a focus on Pharmaceutical Management and finance. He is the author of several patents and co-authors of multiple scientific publications.
Frederick Larcombe, CPA
Chief Financial Officer
Frederick Larcombe is the Chief Financial Officer at EDE. He has previously served in that role for over 20 years at number of companies in the life sciences industry. He has diverse and international experience in operations, raising capital, product commercialization, mergers and acquisitions, as well as numerous other areas. Since 2012 he has served as Chief Financial Officer for PharmApprove, LLC, a privately-held professional services firm which assists pharmaceutical companies with communications to regulatory authorities. From 2009 to 2011 he served as the Chief Financial Officer for iBio, Inc., a publicly-held biotechnology company focused on commercializing proprietary pharmaceutical manufacturing technology. He also served Phytomedics, Inc., a venture capital backed clinical stage pharmaceutical company which focused upon multi-component drugs. Mr. Larcombe served simultaneously as the Chief Financial Officer of Xenomics Inc., a publicly-held developer of DNA-based diagnostic tests and FermaVir Pharmaceuticals, Inc., a publicly-held pharmaceutical development company focused upon a series of pharmaceuticals for the treatment of viral diseases from 2005 to 2007. He was a consultant with Kroll Zolfo Cooper, a professional services firm providing interim management and turn-around services and the Chief Financial Officer of MicroDose Therapeutics, a privately-owned medical device company focused upon developing pulmonary delivery technologies for pharmaceutical products. Mr. Larcombe currently also serves as the Chief Financial Officer for InterCore, Inc, a publicly-held developer of fatigue monitoring systems. Mr. Larcombe received his BS in Accounting from Seton Hall University, was a Certified Public Accountant in public practice, and attended the Executive Development Program at Harvard Business School.
Frederick Larcombe is the Chief Financial Officer at EDE. He has previously served in that role for over 20 years at number of companies in the life sciences industry. He has diverse and international experience in operations, raising capital, product commercialization, mergers and acquisitions, as well as numerous other areas. Since 2012 he has served as Chief Financial Officer for PharmApprove, LLC, a privately-held professional services firm which assists pharmaceutical companies with communications to regulatory authorities. From 2009 to 2011 he served as the Chief Financial Officer for iBio, Inc., a publicly-held biotechnology company focused on commercializing proprietary pharmaceutical manufacturing technology. He also served Phytomedics, Inc., a venture capital backed clinical stage pharmaceutical company which focused upon multi-component drugs. Mr. Larcombe served simultaneously as the Chief Financial Officer of Xenomics Inc., a publicly-held developer of DNA-based diagnostic tests and FermaVir Pharmaceuticals, Inc., a publicly-held pharmaceutical development company focused upon a series of pharmaceuticals for the treatment of viral diseases from 2005 to 2007. He was a consultant with Kroll Zolfo Cooper, a professional services firm providing interim management and turn-around services and the Chief Financial Officer of MicroDose Therapeutics, a privately-owned medical device company focused upon developing pulmonary delivery technologies for pharmaceutical products. Mr. Larcombe currently also serves as the Chief Financial Officer for InterCore, Inc, a publicly-held developer of fatigue monitoring systems. Mr. Larcombe received his BS in Accounting from Seton Hall University, was a Certified Public Accountant in public practice, and attended the Executive Development Program at Harvard Business School.
William A Kinney, PhD
Chief Scientific Officer
Dr. Kinney is a medicinal chemist with greater than 25 years of experience in large pharmaceutical (Wyeth, Johnson & Johnson), biotechnology (Magainin), and non-profit (IHVR) research and development. His research interests include antiviral approaches based on improving the host’s resistance. He has demonstrated expertise in drug design; synthesis; lead optimization of peptides, small molecules, and natural products; and has advanced three molecules into human clinical trials - Perzinfotel (CNS disorders and pain), Squalamine (oncology and AMD), and Trodusquemine (obesity). Concurrently, Dr. Kinney is a faculty member within the Institute for Hepatitis and Virus Research and Director of Business Development for the Natural Product Discovery Institute.
Dr. Kinney is an adjunct faculty member at Drexel University. His scientific contributions include 70 publications and inventorship on 37 issued U.S. patents.
Dr. Kinney is an adjunct faculty member at Drexel University. His scientific contributions include 70 publications and inventorship on 37 issued U.S. patents.
Jacqueline W. Phillips, MD, MBA
Vice President Clinicals
Dr. Williams is Division Chief of Critical Care Medicine and Associate Professor of Pediatrics at Robert Wood Johnson Medical School. She also serves as Adjunct Clinical Assistant Professor of Pharmacy at the Ernest Mario School of Pharmacy of Rutgers, The State University of New Jersey. Board-certified in intensive care, she is Medical Director of the Intensive Care Unit at Bristol-Myers Squibb Children’s Hospital.
In 2002, 2004, and 2006, Dr Williams was selected one of the Best Doctors in America. She has received awards for excellence in research from the Science of Critical Care Medicine, for excellence in teaching from both Robert Wood Johnson and Albert Einstein College of Medicine, and for outstanding service from the Student National Medical Association and New York Medical College.
In addition to pharmacology and care of the critically ill, her areas of interest include toxicity, neurophysiology, bioethics, bloodless medicine, patient safety, performance improvement, and strategic planning.
She is active in the Society of Critical Care Medicine, American Academy of Pediatrics, and National Medical Association.
In 2002, 2004, and 2006, Dr Williams was selected one of the Best Doctors in America. She has received awards for excellence in research from the Science of Critical Care Medicine, for excellence in teaching from both Robert Wood Johnson and Albert Einstein College of Medicine, and for outstanding service from the Student National Medical Association and New York Medical College.
In addition to pharmacology and care of the critically ill, her areas of interest include toxicity, neurophysiology, bioethics, bloodless medicine, patient safety, performance improvement, and strategic planning.
She is active in the Society of Critical Care Medicine, American Academy of Pediatrics, and National Medical Association.
Christiano Butler
Vice President & Head of Operations
Mr. Butler is an Executive Operations Manager with 30 years experience in Clinical Operations and Medical Systems Development. He has a diverse background in Commercial Product Development, Operations Management, Engineering, Customer Support, and Regulatory Compliance. Prior to EDE Pharma, Chris was Vice President of Operations at Mela Sciences where he was responsible for developing an innovative, non-invasive device for the early detection of melanoma. Previously Chris held the roles of Manager Global Systems and Support, and Manager System Engineering at Bayer Health Care respectively. Chris has an excellent record of achievement supported by technical experience, global exposure, well developed interpersonal skills, and an outstanding reputation for problem solving and innovation in the development of products to support human health.
Chris holds a Bachelor of Sciences in Biology, Mathematics, and clinical sciences from the State University of New York. He is a co-author of several patents and a recipients of major honors recognition from Bayer.
Chris holds a Bachelor of Sciences in Biology, Mathematics, and clinical sciences from the State University of New York. He is a co-author of several patents and a recipients of major honors recognition from Bayer.
Scientific Advisory
Professor Winfred C Wang, MD
Department of Hematology, St Jude Children‘s Research Hospital, TN
Dr. Wang has been at St. Jude for 33 years and has been involved entirely in non-malignant hematology over this period. For the past 20 years he has been increasingly focused on clinical research and clinical care of patients with sickle cell disease. He has also been involved with the care of patients with bone marrow failure disorders throughout his career. He continues to enjoy his efforts in these areas.
Professor Wang research interest is in Sickle cell disease and other hemoglobinopathies, Aplastic anemia and other disorders of bone marrow failure, Neutropenia and granulocyte colony-stimulating factor (G-CSF). He is a board certified physician by the National Board of Medical Examiners, the American Board of Pediatrics, and the American Board of Pediatrics, Subspecialty Board of Pediatric Hematology.
Professor Wang is a former US navy and graduated from the University of California , Berkeley in chemistry and obtained his medical degree from the University of Chicago. He is the author of over 190 scientifc peer reviewed publications and co-author and scientific reviewer of over 30 books
Professor Wang research interest is in Sickle cell disease and other hemoglobinopathies, Aplastic anemia and other disorders of bone marrow failure, Neutropenia and granulocyte colony-stimulating factor (G-CSF). He is a board certified physician by the National Board of Medical Examiners, the American Board of Pediatrics, and the American Board of Pediatrics, Subspecialty Board of Pediatric Hematology.
Professor Wang is a former US navy and graduated from the University of California , Berkeley in chemistry and obtained his medical degree from the University of Chicago. He is the author of over 190 scientifc peer reviewed publications and co-author and scientific reviewer of over 30 books